Will New 3D Multiomic Workflow and Leo System Expansion Change Bio-Techne's (TECH) Narrative?

• In December 2025, Bio-Techne’s Lunaphore unit and the Wyss Center for Bio and Neuroengineering in Geneva announced a collaboration to automate simultaneous RNA and protein detection in intact 3D specimens, while the company also expanded the launch of its next-generation Leo System featuring dual-channel fluorescence and high-throughput protein analysis.
• Together, these advances extend Bio-Techne’s spatial and proteomic platforms from 2D into true 3D multiomic workflows, potentially embedding its tools more deeply in cutting-edge disease research, drug discovery, and organoid-based experimentation.
• Next, we’ll examine how the new 3D multiomic workflow initiative could reshape Bio-Techne’s investment narrative and long-term growth drivers.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Bio-Techne Investment Narrative Recap

To own Bio-Techne, you need to believe its tools will stay embedded in high value research and diagnostic workflows even as funding and tariff uncertainties pressure customers. The Lunaphore and Wyss 3D multiomic collaboration and the upgraded Leo System both reinforce the company’s higher margin instrumentation and spatial biology focus, but they do not materially change the near term risk that weak biotech and academic budgets could keep weighing on consumables demand and overall growth.

Among recent announcements, the expanded launch of the next generation Leo System looks most relevant here, because it strengthens Bio-Techne’s automated proteomic franchise that underpins one of its key earnings catalysts: a richer mix of high throughput, higher margin instruments and workflows that can offset some macro funding headwinds if adoption continues to build across pharma and advanced research labs.

Yet even with these technology wins, investors should be aware that prolonged softness in biotech and NIH funding could still...

Read the full narrative on Bio-Techne (it's free!)

Bio-Techne's narrative projects $1.5 billion revenue and $250.1 million earnings by 2028.

Uncover how Bio-Techne's forecasts yield a $69.17 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see Bio-Techne’s fair value between US$60.31 and US$70.24, highlighting a fairly tight spread of views. You can weigh these against the risk that sustained funding pressure on biotech and academic customers could limit how quickly the new 3D and Leo platforms translate into stronger revenue momentum.

Explore 4 other fair value estimates on Bio-Techne - why the stock might be worth as much as 21% more than the current price!

Build Your Own Bio-Techne Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bio-Techne research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bio-Techne research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Techne's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com